Skip to main content
Clinical Trials/JPRN-jRCTs051200147
JPRN-jRCTs051200147CompletedPhase 4

Effect of empagliflozin on urinary albumin excretion and hypoxic injury biomarkers of early phase diabetic kidney disease - EUROBEAT Study

Makino Hisashi0 sites80 target enrollmentStarted: March 5, 2021Last updated:
Conditions

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
>= 20age old to < 85age old (—)
Sex
All

Inclusion Criteria

  • 20 years old or older, less than 85 years old with type 2 diabetes mellitus HbA1c of 6.5% or higher, and less than 10.0%
  • Urinary albumin excretion of 30mg/gCr or higher, and less than 300mg/gCr, and eGFR more than 30ml/min/1.72m2
  • No change in internal use of renin-angiotensin system inhibitors within 3 months of consent
  • No change in internal use of hypoglycemic drugs within 3 months of consent

Exclusion Criteria

  • BMI less than 18.5 kg/m2
  • Patients who diagnosed as chronic glomerulonephritis
  • Patients who are /want to pregnant, or are breast feeding
  • Patients taking SGLT2 inhibitors within 3 months of consent
  • Patients with heart failure of NYHA III or IV New York Heart Association functional classification
  • Patients who diagnosed as acute coronary syndrome or stroke within 3 months of consent
  • Patients who performed PCI or CABG within 3 months of consent

Investigators

Sponsor
Makino Hisashi

Similar Trials